NCT04655716

Urine Alkalinisation to Prevent AKI in COVID-19

Urine Alkalinisation to Prevent Acute Kidney Injury in COVID-19

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Guy's and St Thomas' NHS Foundation Trust · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim is to explore the feasibility and safety of urine alkalinisation in critically ill patients with COVID-19.

Detailed description

Severe acute kidney injury appears to a major part of the SARS-CoV-2 syndrome. Preventing early acute kidney injury may reduce severe AKI as the disease progresses. Urine alkalinisation to prevent binding of SARS-COV-2 to renal tubular epithelial cells is a novel concept that could be used to design other therapies to reduce viral binding. Showing feasibility with this safe and available strategy could be the first step toward other related efforts.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Sodium Bicarbonate 150Meq/L/D5W Inj	Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.

Timeline

• Start date: 2021-07-19
• Primary completion: 2022-06-30
• Completion: 2022-12-31
• First posted: 2020-12-07
• Last updated: 2022-03-15

Locations

1 site across 1 country: United Kingdom